Vienna, Austria

ESTRO 2023

Session Item

Sunday
May 14
10:30 - 11:30
Lehar 4
Tumour radiobiology
Navita Somaiah, United Kingdom;
Pierre Montay-Gruel, Belgium
Proffered Papers
Radiobiology
11:00 - 11:10
Dietary fibre both radiosensitises tumours and spares intestines from acute radiation toxicity
Anne Kiltie, United Kingdom
OC-0428

Abstract

Dietary fibre both radiosensitises tumours and spares intestines from acute radiation toxicity
Authors:

Anne Kiltie1, Chee Kin Then2, Salome Paillas3, Daniel Sescu4, Ryoichi Saito5, Xuedan Wang6, Mariya Misheva7, James McCullagh7, Kevin Foster6, Katherine Vallis2

1University of Aberdeen, Rowett Institute, Aberdeen, United Kingdom; 2University of Oxford, MRC Oxford Institute for Radiation Oncology, Oxford, United Kingdom; 3University of Oxford, Oxford Institute for Radiation Oncology, Oxford, United Kingdom; 4University of Aberdeen, School of Medicine, Medical Sciences and Nutrition, Aberdeen, United Kingdom; 5University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, USA; 6University of Oxford, Department of Zoology, Oxford, United Kingdom; 7University of Oxford, Chemistry Research Laboratory, Oxford, United Kingdom

Show Affiliations
Purpose or Objective

Dietary fibre intake and the gut microbiota have been shown to modulate the efficacies of immunotherapy and chemotherapy treatments, but there have been very few studies in radiotherapy. We previously found that high fibre diets sensitised RT112 xenografts to irradiation by modifying the gut microbiota in immunocompromised mice. As prebiotics can enhance anti-cancer immunity, we hypothesised that dietary fibre and its modification of the gut microbiota can radiosensitise tumours via microbiota secretion of metabolites and/or immunomodulation, in immunoproficient mice.

Material and Methods

C57BL/6 mice were inoculated in the flank with UPPL 1591 mouse bladder tumour cells when starting low (0.2% cellulose) and high fibre (5% psyllium, 5% psyllium plus 10% resistant starch/10% inulin) diets (N=30) and tumours allowed to grow to 100 mm3. In another cohort, the tumours were irradiated with 6 Gy ionising radiation (IR) when they reached 100 mm3 (N=60) and allowed to grow up to 700 mm3. Gut microbiota, metabolomics, and immunity analyses were performed by using 16S rRNA sequencing, ion chromatography-mass spectrometry and IHC. For normal tissue studies, mice received 10-14 Gy (N=84, acute) or 5x5Gy (N=40, late) IR to their lower abdomen, and intestines were studied by crypt assay at 3.75 days.

Results

Psyllium plus inulin significantly decreased tumour (P=0.007) and delayed tumour growth following IR (P<0.001) compared to 0.2% cellulose. It raised Bifidobacterium relative abundance up to 40% (P<0.001) and intratumoural CD8+ cell numbers (P=0.0129 compared to psyllium plus RS). Post-IR, tumour control positively correlated to Lachnospiraceae family abundance (R2=0.534, P=0.016) and caecal butyrate levels (P=0.041). In responders to psyllium plus inulin, increased cytokine and receptor and T cell functional pathways and decreased exhausted CD8+ cells in tumours were found. Psyllium plus RS significantly radiosensitised the tumours compared to 0.2% cellulose and psyllium (P=0.004 and <0.001) and this positively correlated to Bacteroides genus abundance (R2=0.573, P=0.011). Although local immunity was suppressed, psyllium plus RS increased the caecal isoferulic acid level (R2=0.472, P=0.028), associated with a favourable response. Gut microbes also involved in tumour control by psyllium plus resistant starch included Peptostreptococcaceae family, Parasutterella and Faecalibaculum genera, and Muribulaceae family. Furthermore, the two diets mitigated the radiation injury caused by 14 Gy in intestinal crypt assays (P=0.08 and 0.011). All psyllium-containing diets increased caecal short-chain fatty acids (P<0.001), and prevented the delayed weight gain seen with 0.2% cellulose after IR.

Conclusion

Since psyllium plus either RS or inulin improved the radiation therapeutic ratio, prebiotics may be useful in pelvic cancer patients receiving radiotherapy.